HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Gold Prices Slip Slightly in Asia as Silver Nears Record Highs on Dovish Fed Outlook 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Asian Currencies Trade Sideways as Dollar Weakens Ahead of Key U.S. Data 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
ASX Shares Slide After ASIC Imposes A$150 Million Capital Requirement 
Dollar Struggles as Markets Eye Key Central Bank Decisions and Global Rate Outlooks 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Fed Rate Cut Signals Balance Between Inflation and Jobs, Says Mary Daly 
Japan PMI Data Signals Manufacturing Stabilization as Services Continue to Drive Growth 
Australian Consumer Sentiment Slumps in Early December as Inflation Fears Resurface 
Asian Stocks Slide as AI Valuation Fears and BOJ Uncertainty Weigh on Markets 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
NGeneBio, a leading company in molecular diagnostics (MDx) and companion diagnostics (CDx) in South Korea, announced it had established its new subsidiary in the United States. The company said on Monday, July 24, it has set up an artificial intelligence (AI) precision diagnostic firm called NGeneBioAI.
NGeneBio formed this company to tap into the U.S. precision diagnosis market. The plan is to earmark the data-driven cancer genomic diagnostics market in the country through its own precision diagnostic software.
According to The Korea Economic Daily, the formation of NGeneBioAI was fully funded by NGeneBio, which is now standing as its parent company. Its US subsidiary is now expected to play a big role in NGeneBio’s entry into the region’s cancer diagnostics market. It will offer its next-generation sequencing (NGS) precision diagnostic platform as it starts to build its presence in the American market.
Moreover, in addition to services related to cancer data analysis, NGeneBio will also initiate healthcare data analysis technology. The company will create AI-based diagnostic software with the aim of commercializing data-driven early cancer diagnosis apparatus.
“NGENBIO’s precise diagnosis SW technology is being evaluated as excellent in performance and quality by clinicians to the extent that it is being used in clinical trials for cancer patients at domestic and foreign medical institutions,” NGeneBio’s chief executive officer, Choi Dae Chul explained in a press release.
The CEO added, “With the establishment of NGENBIO AI, we will increase the accuracy of cancer precision diagnosis by expanding NGENBIO SW to the US medical market, and speed up the ongoing strategic investment in the CLIA Lab to complete within the year.”
Finally, Korea Biomedical Review reported that the supply of the company’s NGS precision diagnosis product line will also start in earnest via partnership deals with Clinical Laboratory Improvement Amendments (CLIA) Labs in the U.S.
Photo by: NGeneBio Website
